

Influenza Vaccine Strains

- A/Victoria/4897/2022 (H1N1) pdm09-like virus
- A/Thailand/8/2022 (H3N2) - like virus
- B/Austria/1359417/2021 (B/Victoria lineage) - like virus
- B/Phuket/3073/2013 (B/Yamagata lineage) - like virus

Influenza Vaccine Quick Reference

	FLULAVAL®Tetra QIV split virion	FLUZONE® QIV split virion	FLUZONE® HD QIV split virion	AFLURIA® TETRA QIV Split Virion
Vaccine Components	<p><u>Contains:</u></p> <ul style="list-style-type: none"> • Both influenza A and B viral strains • Sodium chloride • Potassium chloride • Disodium hydrogen phosphate heptahydrate • Potassium dihydrogen phosphate • Water for injection • α-tocopheryl hydrogen succinate • Polysorbate 80 <p><u>Preservative:</u> Thimerosal in multidose</p>	<p><u>Contains:</u></p> <ul style="list-style-type: none"> • Both influenza A and B viral strains • Formaldehyde • Sodium phosphate-buffered isotonic sodium chloride solution • Triton® X-100 <p><u>Preservative:</u> Thimerosal in multidose</p>	<p><u>Contains:</u></p> <ul style="list-style-type: none"> • Both influenza A and B viral strains • Octylphenol ethoxylate (octoxinol-9, Triton® X100) • Sodium phosphate-buffered isotonic sodium chloride solution 	<p><u>Contains:</u></p> <ul style="list-style-type: none"> • Both influenza A and B viral strains • Calcium chloride • Dibasic sodium phosphate (anhydrous) • Monobasic potassium phosphate • Monobasic sodium phosphate • Potassium chloride • Sodium chloride • Water for injection <p><u>Preservative:</u> Thimerosal in multidose</p>
	<p><u>Trace amounts:</u></p> <ul style="list-style-type: none"> • Egg protein (ovalbumin) • Sodium deoxycholate • Ethanol • Formaldehyde • Sucrose 	<p><u>Trace amounts:</u></p> <ul style="list-style-type: none"> • Egg protein (ovalbumin) • Sucrose 	<p><u>Trace Amounts:</u></p> <ul style="list-style-type: none"> • Egg protein (ovalbumin) • Formaldehyde • Sucrose 	<p><u>May Also Contain:</u></p> <ul style="list-style-type: none"> • Egg protein (ovalbumin) • Sodium taurodeoxycholate <p><u>Trace Amounts:</u></p> <ul style="list-style-type: none"> • Sucrose • Beta-propiolactone • Neomycin sulfate • Polymyxin B sulfate • Hydrocortisone
	<p><u>DOES NOT Contain:</u></p> <ul style="list-style-type: none"> • Latex • Antibiotic 	<p><u>DOES NOT Contain:</u></p> <ul style="list-style-type: none"> • Latex • Antibiotic • Gelatin 	<p><u>DOES NOT Contain:</u></p> <ul style="list-style-type: none"> • Latex • Antibiotic • Thimerosal 	<p><u>DOES NOT Contain:</u></p> <ul style="list-style-type: none"> • Latex • Gelatin
Presentation	<ul style="list-style-type: none"> • 5 mL multidose vial containing 10 doses 	<ul style="list-style-type: none"> • 5 mL multidose vial containing 10 doses • 0.5 mL prefilled syringe (thimerosal free) 	<ul style="list-style-type: none"> • 0.7 mL prefilled syringe (thimerosal free) 	<ul style="list-style-type: none"> • 5 mL multidose vial containing 10 doses

NOTE: Thimerosal free vaccine is available for those who self-identify as having a diagnosed thimerosal allergy (documentation not required). It may be administered to others who request it. Contact the local Public Health office if requiring thimerosal free vaccine and it is not available at clinic site.

	FLULAVAL®Tetra QIV split virion	FLUZONE® QIV split virion	FLUZONE® HD QIV split virion	AFLURIA® TETRA QIV Split Virion
Population	6 months or older	6 months or older	Adults 65 years or older (QIV 0.5 mL if HD unavailable)	5 years and older
Dose	0.5 mL	0.5mL	0.7 mL	0.5 mL
Schedule	<ul style="list-style-type: none"> Age 6 months to 8 years (inclusive): 1 or 2 Doses – Children 6 months to 8 years who have never received the seasonal influenza vaccine in any previous season should receive 2 doses given a minimum of 4 weeks apart (an interval of less than 28 days is a medication administration error). Advise to have 2nd dose in 1 month. If the child received 1 or more valid doses in any previous season, they should receive 1 dose per season thereafter. 9 years and older: 1 dose per season Adults 65 years or older who have received the regular QIV influenza vaccine this season are NOT to be further immunized with influenza high dose (HD) vaccine the same season. 			
Contraindications	<ul style="list-style-type: none"> Persons with a history of a severe allergic or anaphylactic reaction to a previous flu vaccine dose or any component of a flu vaccine should discuss this with a public health nurse or their physician. Persons who develop Guillain-Barré syndrome (GBS) within 6 weeks of previous flu vaccine. Infants less than 6 months of age. Serious/severe acute illness – defer vaccine until symptoms improve or have resolved. 			
Precautions	<ul style="list-style-type: none"> Severe oculo-respiratory syndrome (ORS) after previous receipt of an influenza vaccine. 			
Instructions for Administration	<ul style="list-style-type: none"> Do not administer vaccine from a vial that has been opened for ≥ 28 days or has expired. To get 10 doses out of a vial, GSK recommends withdrawing each dose into a 1 mL syringe with a needle gauge not larger than 23 G. 	<ul style="list-style-type: none"> Vaccine must be administered from a multidose vial (MDV) that has been opened up to the expiry date indicated on the vial. 	<ul style="list-style-type: none"> Nothing Specific for this Vaccine 	<ul style="list-style-type: none"> Do not administer vaccine from a multidose vial that has been opened for ≥ 28 days or has expired. It is recommended that 0.5 mL or 1 mL syringes be used to minimize any product loss. The number of needle punctures should not exceed 10 per multidose vial.
Special Considerations	<ul style="list-style-type: none"> Gently shake the vial or prefilled syringe and visually inspect for extraneous particulate matter and/or discoloration. If multi-dose vial, gently shake before each use. Date vials when opened. Store at 2°C to 8°C at all times and return to fridge or cooler between uses. Protect from light. Do not freeze or use if vaccine has been frozen. Pre-drawing is not recommended. The ministry recommends that vaccines be administered directly from the fridge or cooler and not warmed to room temperature prior to administration. 			

For more information, refer to: [Saskatchewan Influenza Immunization Policy 2024-2025](#)
[Chapter 10, Biological Products, Saskatchewan Immunization Manual \(SIM\)](#)
[Influenza Fact Sheets](#)
[NACI Statement on seasonal influenza vaccine for 2024-2025](#)